The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

被引：0
|
作者：
Frank Wiesmann
Jan Vachta
Robert Ehret
Hauke Walter
Rolf Kaiser
Martin Stürmer
André Tappe
Martin Däumer
Thomas Berg
Gudrun Naeth
Patrick Braun
Heribert Knechten
机构：
[1] PZB Aachen,HIV&Hepatitis Research Group
[2] University of Erlangen,Roche Pharma
[3] Institute for Clinical and Molecular Virology,Laboratories Thiele
[4] Schloßgarten,Medical Laboratories Berg
[5] University of Cologne,undefined
[6] Institute for Virology,undefined
[7] University of Frankfurt,undefined
[8] Institute for Virology,undefined
[9] Clinical Project Management,undefined
[10] Institute for Immunology and Genetics,undefined
[11] HIV Research,undefined
来源：
AIDS Research and Therapy | / 8卷
关键词：
Saquinavir; Atazanavir; Lopinavir; Amprenavir; Darunavir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors
    Sulkowski, MS
    SEMINARS IN LIVER DISEASE, 2003, 23 (02) : 183 - 193
  • [22] HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G
    Palma, Ana Carolina
    Covens, Kris
    Snoeck, Joke
    Vandamme, Anne-Mieke
    Camacho, Ricardo Jorge
    Van Laethem, Kristel
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (05) : 1075 - 1079
  • [23] HIV-1 PROTEASE INHIBITORS - THEIR DEVELOPMENT, MECHANISM OF ACTION AND CLINICAL POTENTIAL
    PILLAY, D
    BRYANT, M
    GETMAN, D
    RICHMAN, DD
    REVIEWS IN MEDICAL VIROLOGY, 1995, 5 (01) : 23 - 33
  • [24] Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.
    Anderson P.L.
    Fletcher C.V.
    Current HIV/AIDS Reports, 2004, 1 (1) : 33 - 39
  • [25] Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors
    Tie, Yunfeng
    Wang, Yuan-Fang
    Boross, Peter I.
    Chiu, Ting-Yi
    Ghosh, Arun K.
    Tozser, Jozsef
    Louis, John M.
    Harrison, Robert W.
    Weber, Irene T.
    PROTEIN SCIENCE, 2012, 21 (03) : 339 - 350
  • [26] The HIV-1 protease mutation K55R is associated with the presence of the M461/L mutation
    Morgan, E
    Pillay, D
    Cane, P
    Kleim, JP
    Tisdale, M
    Maguire, M
    Macmanus, S
    Yates, P
    Elston, R
    ANTIVIRAL THERAPY, 2003, 8 (03) : U57 - U58
  • [27] Insights into the interaction mechanism of first-generation HIV-1 protease inhibitors with wild-type and mutant (D30N and L76V) enzymes through in-silico based approach
    Pandarinathan, S.
    Jayanthi, S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025,
  • [28] HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress
    Pyrko, Peter
    Kardosh, Adel
    Wang, Weijun
    Xiong, Wenyong
    Schoenthal, Axel H.
    Chen, Thomas C.
    CANCER RESEARCH, 2007, 67 (22) : 10920 - 10928
  • [29] Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir
    Hulskotte, Ellen G. J.
    Feng, Hwa-Ping
    Xuan, Fengjuan
    van Zutven, Marge G. J. A.
    Treitel, Michelle A.
    Hughes, Eric A.
    O'Mara, Edward
    Youngberg, Stephen P.
    Wagner, John A.
    Butterton, Joan R.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (05) : 718 - 726
  • [30] Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir
    Tie, Yunfeng
    Kovalevsky, Andrey Y.
    Boross, Peter
    Wang, Yuan-Fang
    Ghosh, Arun K.
    Tozser, Jozsef
    Harrison, Robert W.
    Weber, Irene T.
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2007, 67 (01) : 232 - 242
12345